Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum

B. C. Wu, E. D. Patel, Alex Ortega Loayza

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Pyoderma gangrenosum (PG) is a rare autoinflammatory condition in which the alteration of neutrophil function and the innate immune response play key roles in its pathogenesis. Cases of PG have been reported in patients being treated with certain medications, which may help us to understand some of the possible pathways involved in the aetiology of PG. The aim of this review is to review the cases of PG triggered by certain drugs and try to thoroughly understand the pathogenesis of the disease. To accomplish this, a PubMed search was completed using the following words: pyoderma gangrenosum, neutrophilic dermatosis, pathophysiology, drug-induced pyoderma gangrenosum. In total, we found 43 cases of drug-induced PG. Most of them were caused by colony-stimulating factors and small-molecule tyrosine kinase inhibitors. We propose that drugs induce PG through various mechanisms such as dysfunctional neutrophil migration and function, dysregulated inflammatory response, promotion of keratinocyte apoptosis and alteration of epigenetic mechanisms. PG is a rare condition with complex pathophysiology and drug-induced cases are even more scarce; this is the main limitation of this review. Understanding the possible mechanisms of drug-induced PG, via abnormal neutrophil migration and function, abnormal inflammation, keratinocyte apoptosis and alteration of epigenetic mechanisms would help to better understand the pathogenesis of PG and ultimately to optimize targeted therapy.

Original languageEnglish (US)
Pages (from-to)72-83
Number of pages12
JournalBritish Journal of Dermatology
Volume177
Issue number1
DOIs
StatePublished - Jul 1 2017

Fingerprint

Pyoderma Gangrenosum
Pharmaceutical Preparations
Keratinocytes
Epigenomics
Neutrophils
Apoptosis
Colony-Stimulating Factors
Skin Diseases
PubMed
Innate Immunity
Protein-Tyrosine Kinases

ASJC Scopus subject areas

  • Dermatology

Cite this

Drug-induced pyoderma gangrenosum : a model to understand the pathogenesis of pyoderma gangrenosum. / Wu, B. C.; Patel, E. D.; Ortega Loayza, Alex.

In: British Journal of Dermatology, Vol. 177, No. 1, 01.07.2017, p. 72-83.

Research output: Contribution to journalReview article

@article{97d72bf2bfdd436aa4fe0baa952d2ca0,
title = "Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum",
abstract = "Pyoderma gangrenosum (PG) is a rare autoinflammatory condition in which the alteration of neutrophil function and the innate immune response play key roles in its pathogenesis. Cases of PG have been reported in patients being treated with certain medications, which may help us to understand some of the possible pathways involved in the aetiology of PG. The aim of this review is to review the cases of PG triggered by certain drugs and try to thoroughly understand the pathogenesis of the disease. To accomplish this, a PubMed search was completed using the following words: pyoderma gangrenosum, neutrophilic dermatosis, pathophysiology, drug-induced pyoderma gangrenosum. In total, we found 43 cases of drug-induced PG. Most of them were caused by colony-stimulating factors and small-molecule tyrosine kinase inhibitors. We propose that drugs induce PG through various mechanisms such as dysfunctional neutrophil migration and function, dysregulated inflammatory response, promotion of keratinocyte apoptosis and alteration of epigenetic mechanisms. PG is a rare condition with complex pathophysiology and drug-induced cases are even more scarce; this is the main limitation of this review. Understanding the possible mechanisms of drug-induced PG, via abnormal neutrophil migration and function, abnormal inflammation, keratinocyte apoptosis and alteration of epigenetic mechanisms would help to better understand the pathogenesis of PG and ultimately to optimize targeted therapy.",
author = "Wu, {B. C.} and Patel, {E. D.} and {Ortega Loayza}, Alex",
year = "2017",
month = "7",
day = "1",
doi = "10.1111/bjd.15193",
language = "English (US)",
volume = "177",
pages = "72--83",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Drug-induced pyoderma gangrenosum

T2 - a model to understand the pathogenesis of pyoderma gangrenosum

AU - Wu, B. C.

AU - Patel, E. D.

AU - Ortega Loayza, Alex

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Pyoderma gangrenosum (PG) is a rare autoinflammatory condition in which the alteration of neutrophil function and the innate immune response play key roles in its pathogenesis. Cases of PG have been reported in patients being treated with certain medications, which may help us to understand some of the possible pathways involved in the aetiology of PG. The aim of this review is to review the cases of PG triggered by certain drugs and try to thoroughly understand the pathogenesis of the disease. To accomplish this, a PubMed search was completed using the following words: pyoderma gangrenosum, neutrophilic dermatosis, pathophysiology, drug-induced pyoderma gangrenosum. In total, we found 43 cases of drug-induced PG. Most of them were caused by colony-stimulating factors and small-molecule tyrosine kinase inhibitors. We propose that drugs induce PG through various mechanisms such as dysfunctional neutrophil migration and function, dysregulated inflammatory response, promotion of keratinocyte apoptosis and alteration of epigenetic mechanisms. PG is a rare condition with complex pathophysiology and drug-induced cases are even more scarce; this is the main limitation of this review. Understanding the possible mechanisms of drug-induced PG, via abnormal neutrophil migration and function, abnormal inflammation, keratinocyte apoptosis and alteration of epigenetic mechanisms would help to better understand the pathogenesis of PG and ultimately to optimize targeted therapy.

AB - Pyoderma gangrenosum (PG) is a rare autoinflammatory condition in which the alteration of neutrophil function and the innate immune response play key roles in its pathogenesis. Cases of PG have been reported in patients being treated with certain medications, which may help us to understand some of the possible pathways involved in the aetiology of PG. The aim of this review is to review the cases of PG triggered by certain drugs and try to thoroughly understand the pathogenesis of the disease. To accomplish this, a PubMed search was completed using the following words: pyoderma gangrenosum, neutrophilic dermatosis, pathophysiology, drug-induced pyoderma gangrenosum. In total, we found 43 cases of drug-induced PG. Most of them were caused by colony-stimulating factors and small-molecule tyrosine kinase inhibitors. We propose that drugs induce PG through various mechanisms such as dysfunctional neutrophil migration and function, dysregulated inflammatory response, promotion of keratinocyte apoptosis and alteration of epigenetic mechanisms. PG is a rare condition with complex pathophysiology and drug-induced cases are even more scarce; this is the main limitation of this review. Understanding the possible mechanisms of drug-induced PG, via abnormal neutrophil migration and function, abnormal inflammation, keratinocyte apoptosis and alteration of epigenetic mechanisms would help to better understand the pathogenesis of PG and ultimately to optimize targeted therapy.

UR - http://www.scopus.com/inward/record.url?scp=85019062446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019062446&partnerID=8YFLogxK

U2 - 10.1111/bjd.15193

DO - 10.1111/bjd.15193

M3 - Review article

C2 - 27864925

AN - SCOPUS:85019062446

VL - 177

SP - 72

EP - 83

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 1

ER -